Hepatitis C virus (HCV) is a major global health burden accounting for around 170 million
chronic infections worldwide. Since its discovery, which dates back to about 30 years ago …

Introduced in 2013–2014, the second‐and third‐wave directly acting antivirals (DAAs) have
strongly enhanced the efficacy and tolerability of anti‐HCV treatment, with a sustained …

Abstract Background Introduced in 2013–2014, the second-and third-wave directly acting
antivirals (DAAs) have strongly enhanced the efficacy and tolerability of anti-HCV treatment …

Hepatitis C virus (HCV) still represents a major public health threat, with a dramatic burden
from both epidemiological and clinical points of view. New generation of direct‐acting …

Hepatitis C virus (HCV) is classified into seven phylogenetically distinct genotypes, which
are further subdivided into related subtypes. Accurate assignment of genotype/subtype is …

Background This study analysed the NS3 and NS5A mutation frequencies, persistence and
drug susceptibility in a cohort of real-life patients, with failed hepatitis C virus (HCV) therapy …

Background: This study analysed the NS3 and NS5A mutation frequencies, persistence and
drug susceptibility in a cohort of real-life patients, with failed hepatitis C virus (HCV) therapy …

ABSTRACT Introduction: Hepatitis C virus (HCV) infection is one of the leading causes of
hepatic disease worldwide. HCV quasispecies are the substrate for selective pressure …

Abstract Background: Hepatitis C virus (HCV) NS3 resistance-associated substitutions
(RASs) reduce HCV susceptibility to protease inhibitors. Little is known about NS3 RASs in …

Warianty lekooporności związane z obniżeniem wrażliwości (ang. resistance-associated
substitutions–RAS) na bezpośrednio działające leki (ang. directly acting antivirals–DAA) …